---
title: "Boundless Bio, Inc. (BOLD.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/BOLD.US.md"
symbol: "BOLD.US"
name: "Boundless Bio, Inc."
industry: "Biotechnology"
---

# Boundless Bio, Inc. (BOLD.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [boundlessbio.com](https://boundlessbio.com) |

## Company Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company’s lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral i...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.42 | 131/604 | - | - | - |
| PB | 0.24 | 12/604 | 0.25 | 0.22 | 0.20 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-10T05:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 2 | 67% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.17 |
| Highest Target | 4.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/BOLD.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/BOLD.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/BOLD.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.